After 6 years of my services as an Editor, it is now time for me to call it a day. From April 2006 to December 2011 is quite a long journey, a journey as long as my undergraduate medical career (MBBS, internship and housejob) and Residency in Dermatology (MD and senior residency). I like to compare these three phases of my medical career, each spanning approximately over 6 years, because they have extracted the best of my abilities in terms of hard work, devotion, commitment, sincerity and dedication alike.

When I took over as Editor, the journal had remained de-indexed for 16 years and three attempts of re-indexing had gone in vain. The journal used to publish 10--12 articles per issue with a volume of 50 pages per issue. We could at the best generate limited number of pharmaceutical companies' advertisements per year. However, these figures hardly could do anything to affect my commitment and motivation and I remained hopeful of getting it re-indexed. There were reasons for this. I was always conscious and respectful about the unparalleled heritage that this journal has. Getting the chance of serving the journal in itself makes one humble and honored at the same time. Medknow had been engaged as publisher and I had an editorial team comprising young and committed dermatologists. There were of, course, some teething problems, but everyone pitched in.

The combined effort bore fruit in 2009 as the journal got re-indexed after 19 years of its de-indexed state. The journal entered the PubMed central (PMC) on October 30, 2009, and got indexed in PubMed on November 5, the same year. Issues from 2008 were linked to the PubMed site and citations were available. Currently, we get approximately 550 articles per year, which means more than 3 articles per 2 days. To accommodate more number of articles and to reduce our rejection rate, we have started bringing out six issues in a year from the current year. The journal has grown in volume, the Sept.--Oct.' 11 issue was of 138 pages and the current issue has a record setting 167 pages! Our main sources of funds are the 10--12 pharmaceutical advertisements/issue, which sometimes also extends to 16. The current acceptance rate of the journal is 16%, as compared to just 6% 2 years back. Presently, it takes about 3--5 months for an original contribution and 7--8 months for a case report to be published. The corresponding figures were 6--8 months and 12--18 months, respectively, 2 years back and you will agree that this is a remarkable improvement.

Another important feature of IJD is its regular citations in MDLinx site, a site most read by US physicians. Some of the articles have been put at the top positions. This is, in fact, a phenomenal event as hardly any Indian journal in any specialty has featured in the site as many times as IJD. The strength of IJD has been its rich content. We have regularly published "Basic Research" articles on various important issues over the last 6 years and good-quality original articles.

We have introduced the section "IJD Symposium" from April--June 2009 issue onward and have published some excellent articles devoted to urticaria, vitiligo surgery, chemical leukoderma, recent advances in psoriasis, dengue and Chikungunya fever, nephrogenic systemic fibrosis, and airborne contact dermatitis. Our objective is to showcase articles on issues of particular relevance to the students, clinicians, and researchers of dermatology in this subcontinent, while we continue to welcome articles with a still wider appeal. We have published articles by some of the world leaders in dermatology like Professors Robert Schwartz, Hywel Williams, James Nordlund, Rafael Fallabella, S. P. Roychowdhury, C. L. Goh, A. K. Bajaj, P. Sugathan, A. J. Kanwar, C. R. Srinivas, Arun Inamadar, to name a few.

We were honored to receive the request to review the classic "Drug Eruption and Reactions" manual by none other than Dr. Jerome Z. Litt. We have been bold enough to ban a group of authors on charges of plagiarism. We have shown our openness by our "no holds barred" attitude, exemplified by the prompt publication of sharp criticism against the article of two of my close aides in the editorial board, including one of my own.

It is now time for the much deserved "Thank you."

I am privileged to thank my two most able colleagues, the Editor-elect, Koushik Lahiri, and Executive Editor, Saumya Panda, for their tireless efforts and dedicated work. I am extremely happy and privileged to hand over the baton to Koushik as the next editor and I am sure he will take the journal to further heights and help bring many more laurels to IJD. I sincerely thank all the past editors for nurturing IJD for more than 5 decades. Special thanks to Dr. B Haldar for giving momentum to the journal from where it has never looked back. I take this opportunity to thank my seniors, Drs. Sujit Ranjan Sengupta, Arijit Coondoo, Debabrata Bandyapadhyay, Sanjay Ghosh, and Ashok Ghoshal, for their unfailing support and guidance. A bunch of young enthusiastic colleagues did a great job for the journal and I extend my heartfelt gratitude to Nilendu Sarma, Manas Chatterjee, Nilay Das, Sudip Ghosh, and Kisalay Ghosh. The execution of my work would not have been as smooth if I did not have my able assistant Tapas Kayal rushing to my aid at every frantic call. I also thank all my hard working editorial team members, the committed editorial and editorial advisory board members, sincere reviewers, erudite contributors, and above all, the selfless unbiased readers. I take this opportunity to thank all the presidents, secretaries, and esteemed executive body members of IADVL, WB branch, over the last 6 years, for their support and co-operation during my tenure. I must acknowledge and thank Dr. D. K. Sahu of Medknow Publications for his help, support, and guidance to get the journal indexed. His house has not only been the publisher for the journal, but also given very important and useful inputs regarding improvement of quality of the journal.

A journal can never run smoothly without the support from the pharmaceutical industry. I hereby wish to record my thanks to M/s Galderma India Pvt. Ltd., Fulford India Ltd., Glenmark Pharmaceuticals, Palsons Drugs and Chemical Industries, Dr. Reddy\'s Laboratories, GSK Dermatologicals, Janssen-Cilag Pharmaceuticals, Sanofi-Aventis Pharma, Johnson and Johnson, Ranbaxy Croslands, Biocon, Bionova, Wyeth Ltd., and Wallace Rivela, who have supplied the necessary oxygen for the journal\'s survival.

This journal has taught me the value of teamwork. Indeed, the satisfaction I savored for the success of the journal with my colleagues far exceeds that of individual accolades and laurels. It taught me to think "we" instead of "I" while sharing success of this journal with others.

It gave me the strength and succor to fight when I was diagnosed to have Hodgkin\'s Lymphoma and was undergoing chemotherapy in 2009. The very hectic schedule of an editor imbibed all the extra time of my life in those days which I would otherwise have spent on brooding and dreading about real and imaginative complications. I was in pain, but did not suffer. The journal taught me to be strong and tough on one hand, and humble and introspective on the other.

I sincerely thank the Almighty God to have given me a chance of serving *Indian Journal of Dermatology* in which my first article was published in 1986. It was an experience that I shall cherish throughout my life.

I, on behalf of "Team IJD," sincerely thank all of you for your kind patronage of IJD and hope you will continue to do the same in the days to come. I wish you all a very happy and prosperous 2012.

Long live IJD!
